What is the optimal perioperative chemotherapy regimen for muscle-invasive bladder cancer?

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Sep 18 / Roche and Genentech

What is the optimal perioperative chemotherapy regimen for muscle-invasive bladder cancer?

Oncology Urinary Bladder Cancer ESMO-2021

Description

Srikala Sridhar gives her thoughts on the VESPER V05 trial comparing dose-dense methotrexate, vinblastine, doxorubicin and cisplatin with gemcitabine plus cisplatin as perioperative treatment in people with muscle-invasive bladder cancer.

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.